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Background: Everolimus-eluting stent (EES) are considered to have better clinical outcomes than other
rapamycin derivative-eluting stents; however, the individual trials may not have sufﬁcient power
to prove it. This meta-analysis aimed to compare clinical outcomes of EES against other rapamycin
derivative-eluting stents.
Methods: We searched Medline, the Cochrane Library, and other internet sources, without language or
date restrictions for articles comparing clinical outcomes between EES and other rapamycin derivative-
eluting stents. Safety endpoints were stent thrombosis (ST), mortality, cardiac death, and myocardial
infarction (MI). Efﬁcacy endpoints were major adverse cardiac events (MACE), target lesion revasculari-
zation (TLR), and target vessel revascularization (TVR).
Results: We identiﬁed 16 randomized controlled trials with 23,481 patients and aweightedmean follow-
up of 18 months. Compared with other rapamycin derivative-eluting stents, EES were associated with
a signiﬁcant reduction in deﬁnite ST [relative risk (RR): 0.45; 95% conﬁdence interval (CI): 0.30–0.69;
p<0.001] and TLR (RR: 0.87; 95% CI: 0.77–0.99; p=0.03). EES also showed a non-signiﬁcant trend toward
reduction indeﬁnite/probable ST (RR: 0.75; 95%CI: 0.56–1.01;p=0.06).However, both groupshad similar
rates of mortality (RR: 0.95; 95% CI: 0.82–1.09; p=0.45), MI (RR: 0.95; 95% CI: 0.82–1.10; p=0.43), and
MACE (RR: 0.94; 95% CI: 0.87–1.02; p=0.35). The stratiﬁed analysis of the included trials showed that
EES was associated with signiﬁcantly lower rate of deﬁnite ST compared with either zotarolimus-eluting
stent (p=0.012) or sirolimus-eluting stent (p=0.006), but not biolimus-eluting stent (p=0.16). In longer
follow-up (>1 year) stratiﬁcation, EES was associated with a signiﬁcant reduction in risk of deﬁnite ST
(p<0.001).
Conclusions: EES is associatedwith a signiﬁcant reduction in deﬁnite ST and TLR for treating patients with
coronary artery disease, compared with a pooled group of other rapamycin derivative-eluting stents.
Biolimus-eluting stent had similar safety and efﬁcacy for treating patients with coronary artery disease,
compared with the EES.
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Introduction
Drug-eluting stents (DES) with controlled release of antipro-
liferative drugs signiﬁcantly reduce the incidence of restenosis
after percutaneous coronary intervention (PCI), compared with
bare metal stents (BMS) [1–3]. Two different classes of highly
lipophilic drugs have been employed on DES platforms in order
to inhibit smooth muscle cell proliferation: drugs of the “limus”
vier Ltd. All rights reserved.
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amily andpaclitaxel [4–8]. Recently, paclitaxel-eluting stents (PES,
axus, Boston Scientiﬁc, Natick, MA, USA) has been withdrawn
rom clinical practice due to its higher incidences of stent throm-
osis (ST) and repeat revascularization, compared with rapamycin
erivative-eluting stents [9].
In contemporary practice, limus-eluting DES, including those
luting everolimus, biolimus A9, zotarolimus, and sirolimus, are
sed worldwide and have been shown to effectively inhibit neoin-
imal hyperplasia after stent implantation [10–15]. However, data
rom experimental studies have suggested that different limus
rugs may have differential effects on re-endothelialization and
ubsequently on vascular healing [16,17]. Indeed, a preclinical
tudy has shown more rapid endothelialization with everolimus-
luting stent (EES) compared with sirolimus-eluting stent (SES)
16].
Apart from SES, several clinical trials reported that biolimus
9-eluting stent (BES) and zotarolimus-eluting stent (ZES) were
on-inferior to EES in treating patients with obstructive coronary
isease [15,18]. In a large overviewof comparative trials, treatment
ith EES signiﬁcantly reduced the risk of repeat revasculariza-
ion and deﬁnite ST compared with SES [19]. However, an updated
eta-analysis demonstrated that the use of EES versus SES was
ssociated with similar incidence of overall clinical events [20].
n a previous meta-analysis, Baber et al. also demonstrated an
nconsistent beneﬁtwith EES using stratiﬁed analysis, and detected
ifferences in the treatment effect across control non-EES strata,
howing reductions in clinical outcomes were substantial in trials
ersus PES, intermediate versus ZES, and smallest against SES [21].
herefore, whether EES has favorable clinical outcomes compared
ith other rapamycin derivative-eluting stents remains unsettled.
The aim of the present study is to compare the clinical perfor-
anceof EESandother limusDZS (namely, BES, ZES, andSES), using
ata from randomized controlled trials (RCTs).
ethods
ata sources and search strategy
We performed a computerized search of Medline, the Cochrane
ibrary, and internet sources for clinical RCTs from January
002 to July 2013 using the medical subject heading terms
everolimus-eluting stent,” as well as a combination of the
erms “biolimus-eluting stent,” “zotarolimus-eluting stent,” and
sirolimus-eluting stent”. We used the Science Citation Index as a
ross reference to identify trials that met the search criteria. Med-
ine was searched using the method described by Biondi-Zoccai
t al. [22,23]. Additional searches for potential trials included the
eferences of previous meta-analyses, review articles, and the fol-
owing congresses: scientiﬁc sessions of the American College of
ardiology, American Heart Association, Transcatheter Cardiovas-
ular Therapeutics, EuroPCR, Chinese Interventional Therapeutics,
nd European Society of Cardiology.
tudy identiﬁcation and data extraction
Citations were screened at title/abstract level and retrieved
s full articles. Criteria for inclusion in the meta-analysis were:
1) randomized trials between EES and comparator rapamycin
erivative-eluting stents; (2) available clinical follow-up data.
tudies of non-randomized data, sub-studies of randomized tri-
ls, and studies with comparison of BMS or polymer-free DES were
xcluded. Three independent investigators (LL Zhu, MH Li, and SJ
ong) extracted the data, which included the trials’ name, dual
ntiplatelet therapy (DAPT) duration, follow-up duration, sample
ize, baseline characteristics, and clinical outcomes in EES andiology 64 (2014) 185–193
comparator rapamycin derivative-eluting stents. Internal validity,
using the Cochrane Collaboration’s tool [24] was assessed by 2
investigators (LL Zhu, SJ Dong) for the risk of bias, according to
allocation sequence generation, allocation sequence concealment,
participants’ andpersonnelblinding, outcomeassessmentblinding,
incomplete outcome data, selective outcome reporting, etc.
Clinical endpoints
The clinical endpoints in thepresentmeta-analysis included: (1)
ST (deﬁnite and deﬁnite/probable), deﬁned by Academic Research
Consortium (ARC) classiﬁcation; (2) mortality; (3) cardiac death;
(4) myocardial infarction (MI); (5) major adverse cardiac events
(MACE, as deﬁned by individual trials included in this meta-
analysis); (6) target lesion revascularization (TLR); and (7) target
vessel revascularization (TVR).
Statistical analysis
We calculated relative risk (RR) and 95% conﬁdence interval
(CI) from the extracted data. We considered both the ﬁxed-
effects model (based on the Mantel–Haenszel method) and the
random-effects model (DerSimonian and Laird method) for the
meta-analyses. Heterogeneity of the effect size across studies was
tested using Q statistics at the p=0.10 level of signiﬁcance. I2 test, a
quantitative measure of inconsistency across studies was also cal-
culated, whereQwas the chi-squared statistic and dfwas its degree
of freedom. Heterogeneity was classiﬁed as low with a value of
I2 < 25%, moderate with 50%, and high with 75%. Forest plots were
generated for graphical presentations of the clinical outcomes.
Stratiﬁed analyses were conducted to explore heterogeneity
potentially caused by discrete factors. Potential publication bias
was assessed by visual inspection of the contour-enhanced fun-
nel plot, in which the logarithm RR was plotted against their
inverse standard error with different signiﬁcant contours. The
Egger’s linear regression test was employed to test for funnel plot
asymmetry at the p<0.10 level of signiﬁcance [25]. A probability
value of <0.05 was considered statistically signiﬁcant. All analy-
ses were performed using STATA 12.0 (Stata Corp., College Station,
TX, USA).
Results
Eligible trials
Sixteen eligible RCTswere identiﬁed and included in thepresent
meta-analysis (Fig. 1) [10,13–15,26,11,27–36]. Out of 16 RCTs, 2
trials compared EES with BES [14,15], 2 trials compared EES with
ZES [11,27], and 12 trials compared EES with SES [10,13,26,28–36].
The majority of the included RCTs were assessed as being at low
risk of bias across all domains of qualities according to theCochrane
Collaboration’s tool (Supplement, Fig. 1).
Baseline characteristics
The characteristics of included trials are shown in Table 1. Data
were analyzed from 11,107 (47.3%) patients who underwent EES
implantation and 12,374 (52.7%) patients underwent comparator
rapamycin derivative-eluting stent implantation (overall patient
numbers, n=23,481). Patients’ follow-up ranged from 12 to 36
months, with a weighted mean follow-up time of 18 months. The
RESET and NEXT trial from Japan had older patients (69 years) and
higher prevalence of diabetesmellitus (45%, 46%) [14,32]. TheXAMI
trial studied the performance of EES and SES for patientswith acute
myocardial infarction [34].
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tent thrombosis
All 16 RCTs contributed to the analysis of deﬁnite/probable ST
ccording to ARC classiﬁcation. Thirteen trials were included in
he analysis for this endpoint, as 3 trials had no ST event. The fre-
uency of deﬁnite ST was 0.27% (30/11,107) in the EES group, and
.67% (83/12,374) in the comparator DES group. Themeta-analysis
howed a signiﬁcant reduction in the risk of deﬁnite ST with the
se of EES (RR: 0.45, 95% CI: 0.30–0.69; p<0.001) (Fig. 2). Although
he statistical signiﬁcance was marginal, there was a trend toward
able 1
eatures of randomized trials included after full-text inspection.
RCTs Year published EES Comparator DES FLU, months
COMPARE II 2013 EES BES 12
NEXT 2013 EES BES 12
RESOLUTE 2011 EES ZES 24
TWENTE 2013 EES ZES 24
ESSENCE DIABETES 2010 EES SES 12
BASKET-PROVE 2010 EES SES 12
EXCELLENT 2010 EES SES 12
Burzotta et al. 2011 EES SES 12
LONG-DES III 2011 EES SES 12
ISAR-TEST 4 2011 EES SES 36
RESET 2012 EES SES 12
SORT OUT IV 2012 EES SES 24
XAMI 2012 EES SES 12
Sakakibara et al. 2012 EES SES 12
CIBELES 2013 EES SES 12
Target I 2013 EES SES 12
CS, acute coronary syndrome; BES, biolimus-eluting stent; DAPT, dual antiplatelet thera
LU, follow-up; NA, not available; RCTs, randomized controlled trials; SES, sirolimus-elutrandomized clinical trials were identiﬁed.
low incidence of deﬁnite/probable ST in EES group (RR: 0.75, 95%
CI: 0.56–1.01; p=0.06). Therewas no evidence of statistical hetero-
geneity among these RCTs (p heterogeneity =0.81 for deﬁnite ST; p
heterogeneity =0.71 for deﬁnite/probable ST).
Mortality and myocardial infarctionMortality and MI were reported in all RCTs. The use of EES
versus other rapamycin derivative-eluting stents resulted in a sim-
ilar risk of mortality (RR: 0.95, 95% CI: 0.82–1.09; p=0.45) and MI
DAPT, months Sample size Age, years Male, % DM, % ACS, %
12 912/1795 63/63 74/74 22/22 58/58
3 1618/1617 69/69 77/77 46/46 16/17
6 1152/1140 64/64 77/77 23/24 53/54
12 694/697 65/64 73/73 21/23 51/52
12 149/151 63/64 52/66 100/100 43/40
12 774/775 66/66 76/74 15/18 65/65
6 1079/364 63/63 65/63 37/41 53/48
12 75/75 64/65 85/75 25/33 49/39
12 224/226 63/63 74/66 32/27 39/46
6 652/1951 67/67 77/75 29/29 40/42
3 1597/1600 69/69 78/76 45/45 18/18
12 1390/1384 64/64 76/75 14/14 42/43
12 404/221 61/62 73/75 9/11 100/100
12 50/50 64/76 67/65 33/37 NA/NA
12 106/101 65/63 20/14 41/32 NA/NA
12 231/227 60/59 68/69 17/14 72/71
py; DES, drug-eluting stent; DM, diabetes mellitus; EES, everolimus-eluting stent;
ing stent; ZES, zotarolimus-eluting stent.
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RR: 0.95, 95% CI: 0.82–1.10; p=0.49) (Fig. 3A). Heterogeneity was
ot signiﬁcant among trials (p heterogeneity =0.85 for mortality; p
eterogeneity =0.83 for MI) (Fig. 3B).arget lesion revascularization and major adverse cardiac events
The pooled RR showed signiﬁcant difference in risk of TLR
etween EES and non-EES groups (RR: 0.87, 95% CI: 0.77–0.99;
ig. 2. Forest plotswith relative ratios from the trials. Size of datamarkers indicatesweigh
T.
ES, everolimus-eluting stent; RR, relative risk; ST, stent thrombosis.iology 64 (2014) 185–193
p=0.03) (Fig. 3C). In terms of MACE, the deﬁnition was described
and reported in all 16 trials (Supplement, Table1). ThepooledRR for
MACEwas 0.94 (95% CI: 0.87–1.02; p=0.17). Therewas no evidence
of heterogeneity among the trials (p heterogeneity =0.76 for TLR;
p heterogeneity =0.47 for MACE) (Fig. 3D). The pooled results for
cardiac death and TVR showed there were no statistical differences
between groups (p=0.13 and p=0.86, respectively) (Supplement,
Fig. 2).
t of each trial included in themeta-analysis: (A) deﬁnite ST and (B) deﬁnite/probable
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tratiﬁed analyses for clinical outcomesStratiﬁed analyses were performed for deﬁnite ST and deﬁnite/
robable ST to evaluate consistency of our main ﬁndings (Fig. 4).
n longer follow-up (>1 year) stratiﬁcation, EES was associated
ig. 3. Forest plots with relative ratios from the trials. Size of data markers indicates w
C) MACE, and (D) TLR.
ES, everolimus-eluting stent; MACE, major adverse cardiac event; RR, relative risk; ST, siology 64 (2014) 185–193 189
with a signiﬁcant reduction in risk of deﬁnite ST (p<0.001). In the
different rapamycin derivative-eluting stent stratiﬁcation, only
BES presented a similar risk of deﬁnite ST compared with the
EES. The stratiﬁed sub-analyses for other clinical outcomes are
presented as supplementary material (Supplement, Figs. 3 and 4).
eight of each trial in the meta-analysis: (A) mortality, (B) myocardial infarction,
tent thrombosis; TLR, target lesion revascularization.
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ublication bias
The contour-enhanced funnel plots for the studied clinical end-
oints did not reveal asymmetry. Assessment of publication bias
sing logarithm of relative risk demonstrated a symmetric funnel
lot, showing no evidence of publication bias (Fig. 5). The Egger’s
egression testswere performed and conﬁrmed no publication bias
p=0.72 for deﬁnite ST, p=0.53 for deﬁnite/probable ST, p=0.37 for
ortality, p=0.90 for MI, p=0.45 for TLR, and p=0.69 for MACE).inued ).
Discussion
Our meta-analysis of 16 RCTs with 23,481 patients has shown
that EES is associatedwith a signiﬁcant reduction in deﬁnite ST and
TLR, compared with other rapamycin derivative-eluting stents in a
weighted mean follow-up of 18 months. There were no signiﬁcant
differences in the riskofmortality,MI, andMACEbetween theuseof
EES andnon-EES stents. In the stratiﬁed analyses, the risk reduction
with EES for deﬁnite ST was primarily against SES and ZES.
Y.-J. Zhang et al. / Journal of Cardiology 64 (2014) 185–193 191
Fig. 4. Stratiﬁed sub-analyses of the randomized trials. The pooled estimates for deﬁnite ST, deﬁnite/probable ST are shown as relative risk. Boxes indicate point estimates
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search in September 2011. In the present study, we have reported
the largest number of patients who experienced EES implantation
and shown a signiﬁcantly lower incidence of TLR compared with
all other rapamycin derivative-eluting stents. Presumably, thend lines for 95% conﬁdence intervals.
ES, biolimus-eluting stent; DES, drug-eluting stent; EES, everolimus-eluting stent;
Several studies have evaluated the performance of EES against
MS or other DES [10,11,15,29,33,37–40]. A recent comprehensive
eta-analysis has reported that EES reduces the incidence of ST
ompared with BMS [41]. Similarly, studies have shown that EES
s associated with a signiﬁcant reduction in clinical events com-
ared with PES [37,38]. Although recent studies have suggested
hat EES has the most favorable safety and efﬁcacy proﬁle, the dif-
erence in clinical outcomes (including ST, TLR, andMACE) between
ES and other limus-eluting stents remains to be proven conclu-
ively.We, for the ﬁrst time, have shown that EES has a signiﬁcantly
mproved clinical performance comparedwith other limus-eluting
tents.
ST incidence associated with devices is different between EES
nd other limus-eluting stents. Jensen et al. have shown that EES
s associated with a lower incidence of ST compared with SES at 2-
ear follow-up, then concluded that the EES is non-inferior to the
ES for both patient-related and device-related clinical outcomes
33].Moreover, 2-year follow-up from the Resolute all-comers trial
as shown similar safety and efﬁcacy outcomes between EES and
ES, although there was a trend toward less ST in the EES group
p=0.077) [11]. Additionally, in the COMPARE II trial, although no
tatistical difference existed in the incidence of deﬁnite ST between
ES and BES (p=0.38), numerically it appeared that EES had less
ncidence of ST at 1 year follow-up (4/912 in EES vs. 13/1795 in
ES) [15]. Our study with pooled data from 16 RCTs has demon-
trated that EES is associated with a signiﬁcantly lower incidence
f ST. The stratiﬁed analysis, however, conﬁrmed that this beneﬁt
s largely against SES and ZES, not BES. Several ex vivo experimen-
al studies have also demonstrated that various limus drugs may
ave a differential inﬂuence on re-endothelialization and delayed
ascular healing, the biological precursor for ST [17,42].
Everolimus and other limus drugs are all inhibitors of themam-
alian target of rapamycin, and have proven efﬁcacy in inhibiting
eointimal hyperplasia. However, several previous studies have
roposed that everolimus may have more potent effect and EES
mplantation may lead to reduction in TLR [17,37]. Similarly, airolimus-eluting stent; ST, stent thrombosis; ZES, zotarolimus-eluting stent.
meta-analysis of 11 RCTs (12,869 patients) has shown that EES is
associated with a signiﬁcantly reduced risk of repeat revasculari-
zation compared with SES (OR: 0.85, 95% CI: 0.71–1.00; p=0.047)
[43]. Unfortunately, the clinical outcomes of the APPENDIX-
AMI trial with 977 patients in this meta-analysis have not been
formally published yet. Conversely, another updatedmeta-analysis
of 8 RCTs including 11,167 patients has shown no signiﬁcant effect
of EES on re-interventions as compared with SES (RR: 0.86, 95% CI:
0.72–1.04; p=0.12) [20]. These conﬂicting results may be caused
by insufﬁcient power to achieve the statistical difference in the
latter meta-analysis with only 8 trials identiﬁed during the lastFig. 5. Contour-enhanced funnel plot of the randomized trials for target lesion
revascularization, suggesting no publication bias was found.
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nderlying mechanism of low TLR rate in the EES group is partially
ue to effective inhibition of neointimal hyperplasia in long-term
ollow-up [17].
Together with the antiproliferative drug, the stent platform
nd polymer with the varying stent designs may also play a
ajor role in adverse events and ST [44]. In Target I trial, Gao
t al. reported that SES with novel biodegradable polymer has
imilar safety and efﬁcacy for the treatment of patients with de
ovo lesions compared with the EES [13]. In addition, ST can
e also attributed to patient, procedural, and lesion factors [44].
urthermore, recentmeta-analyses have reported that the patients
llocated to biodegradable polymer DES showed signiﬁcantly less
ate/very late ST [45,46]. Although several DES in the comparator
ontrol group used biodegradable polymers in the present study,
ES group still had lower incidence of deﬁnite ST. Therefore, our
ata support the notion that EES offers superior safety and efﬁcacy
ompared with other limus-eluting stents.
Recently the concept of “novel rapamycin derivative drugs,”
biodegradable polymers or polymer-free,” and “new backbone
aterials” has been highlighted for DES design [47,48]. This is
ither safety considered, on the basis of decreasing most of the
ncidence of ST, or efﬁcacy considered (on basis of reducing in-stent
estenosis). The underlying principle is that, even if each compo-
ent of DES is technically possible or achievable, this would not
eﬁnitely improve clinical outcomes, given the unknown deﬁcits
n some components, especially at longer-term follow-up. There-
ore, tomake it possible, it is necessary to understandwhy different
imus drugs react in a particular way, how individual DES perform
n different clinical settings, at least to exert a synergistic effect of
ll components of DES to its safety and efﬁcacy.
imitations
Our study has several limitations. Firstly, the meta-analysis
hares the limitations of the original trials, the results were based
n the trial level. Secondly, the comparator DES groups include SES,
ES, BES together,whichhavedifferent stent designs andpolymers.
owever, we have employed several stratiﬁed analyses to distin-
uish the performance of different rapamycin derivative-eluting
tents compared with EES. Thirdly, several studies only enrolled
atients with speciﬁc clinical presentations (such as chronic total
cclusion, hemodialysis), and this may have had invisible bias.
ourthly, although 4 trials have more than 1-year follow-up out-
omes, it is preferable to address the clinical performance in the
onger-term follow-up. Fifthly, the deﬁnitions (e.g. MACE and MI)
sed in each trial were different, which makes direct compari-
on less precise. Finally, whether the TLR was driven by clinical
schemia was not reported in several studies. However, despite
hese limitations, the large sample size of the present study
n=23,481) provided sufﬁcient power to evaluate the impact of
ES on each clinical outcome.
onclusions
EES is associated with a signiﬁcant reduction in deﬁnite ST and
LR for treating patients with coronary artery disease, compared
ith a pooled group of other rapamycin derivative-eluting stents
nameanweighted follow-upof18months. Longer-termfollow-up
s warranted to demonstrate persistent safety and efﬁcacy beneﬁts
f EES. BES had similar safety and efﬁcacy for treating patientswith
oronary artery disease, compared with the EES.ppendix A. Supplementary data
Supplementary data associatedwith this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.jjcc.2014.01.007.
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